Browse by



Recent Submissions

  • Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex 

    Weir, Scott J.; Dandawate, Prasad; Standing, David; Bhattacharyya, Sangita; Ramamoorthy, Prabhu; Rangarajan, Parthasarathy; Wood, Robyn; Brinker, Amanda E.; Woolbright, Benjamin L.; Tanol, Mehmet; Ham, Tammy; McCulloch, William; Dalton, Michael; Reed, Gregory A.; Baltezor, Michael J.; Jensen, Roy A.; Taylor, John A., III; Anant, Shrikant (Springer Nature, 2021-05-31)
    Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic malignancies. Its clinical utility as an oral anticancer agent, however, ...
  • A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies 

    Williamson, Stephen K.; Johnson, Gary A.; Maulhardt, Holly A.; Moore, Kathleen M.; McMeekin, D. S.; Schulz, Thomas K.; Reed, Gregory A.; Roby, Katherine F.; Mackay, Christine B.; Smith, Holly J.; Weir, Scott J.; Wick, Jo A.; Markman, Maurie; diZerega, Gere S.; Baltezor, Michael J.; Espinosa, Jahna; Decedue, Charles J. (Springer Verlag, 2015-05)
    PURPOSE: This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary tumor response of a nanoparticulate formulation of paclitaxel (Nanotax®) administered ...